(Q28296434)

5

Andres Lozano

0 references

Charles Warren Olanow

26

C Warren Olanow

0 references

Karl Kieburtz

24

Karl Kieburtz

0 references

Jeffrey H Kordower

25

Jeffrey H Kordower

0 references

John G Nutt

23

John Nutt

0 references

Matthew B. Stern

18

Matthew Stern

0 references

Roy A. E. Bakay

11

Roy Bakay

0 references

Jerrold L Vitek

7

Jerrold Vitek

0 references

author name string

William J Marks

1

0 references

Raymond T Bartus

2

0 references

Joao Siffert

3

0 references

Charles S Davis

4

0 references

Nicholas Boulis

6

0 references

Mark Stacy

8

0 references

Dennis Turner

9

0 references

Leonard Verhagen

10

0 references

Raymond Watts

12

0 references

Barton Guthrie

13

0 references

Richard Simpson

15

0 references

Michele Tagliati

16

0 references

Ron Alterman

17

0 references

Gordon Baltuch

19

0 references

Philip A Starr

20

0 references

Paul S Larson

21

0 references

Jill L Ostrem

The scientific and clinical basis for the treatment of Parkinson disease (2009).

22

0 references

language of work or name

English

0 references

publication date

December 2010

0 references

published in

Lancet Neurology

0 references

volume

9

0 references

issue

12

0 references

page(s)

1164-72

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970254-4

7 January 2021

GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970254-4

7 January 2021

Functional recovery in parkinsonian monkeys treated with GDNF

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970254-4

7 January 2021

Neurturin, a relative of glial-cell-line-derived neurotrophic factor

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970254-4

7 January 2021

Striatal delivery of CERE-120, an AAV2 vector encoding human neurturin, enhances activity of the dopaminergic nigrostriatal system in aged monkeys.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970254-4

7 January 2021

Neurturin exerts potent actions on survival and function of midbrain dopaminergic neurons

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970254-4

7 January 2021

AAV2-mediated delivery of human neurturin to the rat nigrostriatal system: long-term efficacy and tolerability of CERE-120 for Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970254-4

7 January 2021

Striatal delivery of neurturin by CERE-120, an AAV2 vector for the treatment of dopaminergic neuron degeneration in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970254-4

7 January 2021

Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970254-4

7 January 2021

Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970254-4

7 January 2021

Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970254-4

7 January 2021

Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970254-4

7 January 2021

Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970254-4

7 January 2021

Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970254-4

7 January 2021

Point source concentration of GDNF may explain failure of phase II clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970254-4

7 January 2021

Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970254-4

7 January 2021

Continuous low-level glial cell line-derived neurotrophic factor delivery using recombinant adeno-associated viral vectors provides neuroprotection and induces behavioral recovery in a primate model of Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970254-4

7 January 2021

Long-term clinical improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970254-4

7 January 2021

Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970254-4

7 January 2021

What features improve the accuracy of clinical diagnosis in Parkinson's disease: A clinicopathologic study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970254-4

7 January 2021

The Parkinson's Disease Questionnaire (PDQ-39): development and validation of a Parkinson's disease summary index score.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970254-4

7 January 2021

The MOS 36-ltem Short-Form Health Survey (SF-36)

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970254-4

7 January 2021

Bioactivity of AAV2-neurturin gene therapy (CERE-120): differences between Parkinson's disease and nonhuman primate brains.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970254-4

7 January 2021

The clinically important difference on the unified Parkinson's disease rating scale.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970254-4

7 January 2021

Transgene expression, bioactivity, and safety of CERE-120 (AAV2-neurturin) following delivery to the monkey striatum

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970254-4

7 January 2021

Use of placebo surgery in controlled trials of a cellular-based therapy for Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970254-4

7 January 2021

Science and ethics of sham surgery: a survey of Parkinson disease clinical researchers

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970254-4

7 January 2021

Transplantation of embryonic dopamine neurons for severe Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970254-4

7 January 2021

A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970254-4

7 January 2021

Regulatable promoters and gene therapy for Parkinson's disease: is the only thing to fear, fear itself?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970254-4

7 January 2021

Dopaminergic transplantation for Parkinson's disease: current status and future prospects

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970254-4

7 January 2021

Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970254-4

7 January 2021

10.1016/S1474-4422(10)70254-4

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

PubMed publication ID

20970382

1 reference

Consolidated OpenCitations Corpus – April 2017